Substance
ID:1053
Names and Identifiers
Brand Name
LobakMiorilaxMuskelAlinamBanabinRilansylRilaxTranrilaxBanabil-sintyalMuskel-TrancopalRexanRillasolSuprotanTanafolTrancoteBanabin-syntyalBisinaChlomedinonMio-SedRilassolSupotranTrancopalTransanateBanabin-SintyalClorilaxMyolespenPhenarolRilaquilRilasol
Synonyms
Chlormezanonum [INN-Latin]Clormezanone [DCIT]DichloromezanoneChlormethazanoneChlormethazoneClormetazanoneClormetazonChlormezanone [BAN:INN:JAN]ChlormezanonClormezanona [INN-Spanish]Chlormezanonedl-ChlormezanoneDichloromethazanone
IUPAC Traditional name
chlormezanone
IUPAC name
2-(4-chlorophenyl)-3-methyl-1$l^{6},3-thiazinane-1,1,4-trione
Properties
Physical Property
Hydrophobicity(logP)
1.3
Solubility
2500 mg/L (hardly soluble)
Molecule Details
Drug Groups
approved; withdrawn
Description
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem]
Indication
Used in the management of anxiety and in the treatment of muscle spasm.
Pharmacology
Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Affected Organisms
Humans and other mammals
References
•
Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8.
[Pubmed]
•
Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6.
[Pubmed]
•
Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4.
[Pubmed]
•
Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8. Pubmed
• Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6. Pubmed
• Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4. Pubmed
• Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9. Pubmed